Exploring the Utility of APN1607 as a First In Class Diagnostic Marker for Tauopathies for Earlier Identification of Patients
Time: 1:15 pm
day: Conference Day One
Details:
- Discussing and reviewing landscape of imaging markers for tau for neurodegenerative disorders
- Discussing the biological properties of APN1607 as a novel first in class PET tracer for 3R and 4R tauopathies
- Reviewing the clinical results on the utility of APN1607 across the spectrum of 3R and 4R tauopathies including AD, PSP, FTD and CTE
- Exploring progress and challenges for development and approval of tau imaging agents
